The effects of IL-1 receptor antagonist on beta amyloid mediated depression of LTP in the rat CA1 in vivo.
Beta-amyloid (Abeta) is a neuro-peptide implicated in the pathogenesis of Alzheimer's disease (AD). Abeta-peptide is known to disrupt cellular processes, including synaptic plasticity. To date, the precise mechanisms leading to the Abeta-mediated impairment of normal neurophysiological function still remains elusive. A rise in the pro-inflammatory cytokine interleukin-1-beta (IL-1beta) has been previously reported, following Abeta peptide insult. IL-1beta in turn, activates a cascade of pro-apoptotic markers, gradually leading to cell death. In this work, we have investigated the possible protective effects of interleukin-1 receptor antagonist (IL-1ra) on the effects of Abeta-peptide on long-term potentiation (LTP) in the CA1 region of the rat hippocampus in vivo. We observed a significant depression of LTP in the group of animals that received intracerebroventricular (icv) injection of Abeta-peptide (1-40) compared with control animals injected with vehicle. Administration of IL-1ra alone (icv) also resulted in a depression of LTP; however, there was no change in the baseline synaptic response. Combined injection of Abeta(1-40) + IL-1ra caused an attenuation of the effects observed with Abeta(1-40) alone for a period of up to 15 min following LTP induction; rescuing post-tetanicpotentiation (PTP). Gradually however, EPSP-values declined to produce a level of LTP similar to that observed following treatment with Abeta(1-40) alone. These results suggest that the acute Abeta-mediated impairment of PTP and LTP may be partial as a result of activation of an inflammatory response and the release of IL-1beta. The attenuation of plasticity by IL-1ra alone supports the theory that low levels of IL-1beta are required for normal synaptic plasticity. The limited rescue of the Abeta-mediated effects on LTP, in the presence of IL-1ra, may represent the short half life found with this receptor antagonist in vivo.
Schmid
Adrien W
AW
Institute of Neuroscience, Trinity Collegeof Dublin, Ireland.
Lynch
Marina A
MA
Herron
Caroline E
CE
D016229:Amyloid beta-Peptides / Q000378:metabolism*; D000704:Analysis of Variance; D000818:Animals; D004558:Electric Stimulation; D004567:Electrodes, Implanted; D019706:Excitatory Postsynaptic Potentials; D006624:Hippocampus / Q000502:physiology*; D053590:Interleukin 1 Receptor Antagonist Protein / Q000378:metabolism*; D017774:Long-Term Potentiation / Q000502:physiology*; D008297:Male; D010446:Peptide Fragments / Q000378:metabolism*; D011336:Probability; D051381:Rats; D017208:Rats, Wistar; D013997:Time Factors
D016229:Amyloid beta-Peptides; D053590:Interleukin 1 Receptor Antagonist Protein; D010446:Peptide Fragments; C078592:amyloid beta-protein (1-40)